May 13, 2013
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business

May 8, 2013
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Latest ASX stock price

All prices delayed at least 20 minutes.
Source: ASX Inc.

News Release

Bioniche Announces Webcast of Fiscal 2003 First Quarter Results Conference Call

31/10/02

BELLEVILLE, Ontario, October 31, 2002 - Bioniche Life Sciences, (BNC: TSX), will hold a conference call to discuss its fiscal 2003 first quarter results on Friday, November 1 at 10:00 a.m. EST.

A live audio webcast of the conference call will be available through www.bioniche.com and www.financialdisclosure.ca. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available at www.bioniche.com and www.financialdisclosure.ca.

A telephone replay of the conference call will also be available from approximately 12:30p.m. EST on November 1 through November 8, 2002. To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation number 1303103.

About Bioniche Bioniche Life Sciences Inc is a leading Canadian biopharmaceutical company that develops, manufactures and markets proprietary products for human and animal markets worldwide. The company is developing a pipeline of anti-cancer therapies based on its proprietary mycobacterial cell wall technologies. The Company has 230 employees worldwide in four business units: Bioniche Pharma, Bioniche Therapeutics, Bioniche Animal Health, and Bioniche Food Safety. For more information visit www.bioniche.com.

Bioniche Life Sciences Inc. trades on the Toronto Stock Exchange (TSX) under the symbol “BNC” and currently has 27,868,427 shares outstanding.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health